about
Flow-Based Single Cell Deposition for High-Throughput Screening of Protein LibrariesAn Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other CancersIn vitro characterization of genetically expressed absorbing proteins using photoacoustic spectroscopyFc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression.The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells.Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies.TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells.Genetically engineered T-cells for adoptive immunotherapy.Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastomaAdoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015.Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes.CD19 chimeric antigen receptor T cell therapy for haematological malignancies.Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy.Autologous stem cell transplantation outcomes in elderly patients with B cell Non-Hodgkin Lymphoma.TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors.Genetic Regulation of Fate Decisions in Therapeutic T Cells to Enhance Tumor Protection and Memory Formation.Fluorescence-guided development of a tricistronic vector encoding bimodal optical and nuclear genetic reporters for in vivo cellular imaging.Artemisinin therapy and severe delayed haemolysis.Evolving adoptive cellular therapies in urological malignancies.Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells.Transiently redirected T cells for adoptive transfer.Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b.Red-emitting luciferases for bioluminescence reporter and imaging applications.2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells.2B4 (CD244) signaling via chimeric receptors costimulates tumor-antigen specific proliferation and in vitro expansion of human T cells.Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors.Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia.A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells.Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis.A dual-color far-red to near-infrared firefly luciferin analogue designed for multiparametric bioluminescence imaging.An inducible caspase 9 safety switch for T-cell therapy.Radiographic viewing conditions at Johannesburg Hospital.Rapid generation of EBV-specific cytotoxic T lymphocytes resistant to calcineurin inhibitors for adoptive immunotherapy.T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy.Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease.Functional characterization of alloreactive T cells identifies CD25 and CD71 as optimal targets for a clinically applicable allodepletion strategy.Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes.Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor.
P50
Q27312627-80B50DB1-CDBA-4989-87B6-2A2DF0C60F00Q28551080-DE9330C5-5190-4D5C-BF1C-7B71459E59A9Q30446419-421593E1-BB0F-4B90-9C2F-F19C03718B7DQ33707098-CF9E897E-895A-4FDF-8A0C-46A40D58A498Q33713042-557CE6BF-AA33-4CCD-9604-CB38BFB03046Q33756262-DF51C415-3B92-46D9-B15B-9973638DB0CFQ34353696-3C3B227A-6BCC-4A70-B5BC-A5CD4AC86D6AQ34485485-D16F7B43-0F48-452A-BEF7-E64F11AE874AQ34499653-856497D2-9517-4BB3-9070-FC6452A317E7Q34999141-723ED9AE-D50A-4135-AFF3-0F1FD3DA1D3BQ35604043-A91B33D9-0731-47F6-8BA2-E0E1E33B9FE3Q35641721-9830CEBB-A2E1-481C-B8F7-682A940F22AAQ36059585-AE647986-91D1-479F-B089-7A44663857A0Q38370975-8BA7B107-9FC6-4D2F-B1BB-B3F05A143D3FQ38379085-D39ED711-C4BE-4B1C-A229-0B73DEDE17ABQ38539561-E0227201-FFAA-4302-A373-80C79B2E9667Q38769829-C8C128E2-3C2D-488A-ADA8-15003C8DEA88Q38883261-489F766D-37BB-423E-9352-099AE66D6154Q38889816-7911D498-0996-4D6B-B078-8351D4D3DA46Q38889816-A5384881-F37A-444D-A9B9-B5E70FCD3E8EQ39102150-5CF556A9-4D1E-4831-8A6B-C21F7A082C7AQ39359095-73604615-C030-4A32-BB23-9E7F09740456Q39408105-FBED7483-E9B4-40C3-819D-1EBFB2175FA8Q39617593-D8678DB2-D319-4863-A1FE-0B7733017E25Q39655872-A9A32B84-0F89-45AE-8ED1-F7916B220BB1Q39800473-179AE006-BBBF-4D97-BA2E-D1383023EB4AQ39819715-66D0C338-F85F-4C5A-856B-1B3D8AA5A5ACQ39861923-65EFE13E-46D7-4B25-9CA6-C391AC50012CQ40338282-63F83753-8895-4278-A4CF-60DA04C83F69Q40362702-002E584C-A8F7-4F86-A0D5-13E940A305FBQ40404804-E7B769AF-41EE-406C-8016-114392AD9E72Q40457809-A6645A8C-F397-4F24-87CC-833B25EC502AQ41484053-79F70C0E-4824-447F-B069-B0CA0F5F3EA7Q41768001-C9CC5124-66EB-45AB-A6B9-1555D89BF22AQ42090875-1CB08705-DDF9-445D-85FC-4C9557F9E9FDQ42253762-7438D5C9-B2FD-4D1F-9E65-662777DCEAC8Q42333881-EE877FC3-7EEE-4323-AC32-BF833B1F473BQ43273411-AE67DCE6-FD0F-4AB1-8937-E6D075CC441BQ44317423-80AD8D9E-9ED8-4141-9A19-8B103C8CC0FBQ45145816-ED34395F-8480-443F-BDD5-CEF5B4CB5086
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Martin Pule
@ast
Martin Pule
@en
Martin Pule
@es
Martin Pule
@nl
Martin Pule
@sl
type
label
Martin Pule
@ast
Martin Pule
@en
Martin Pule
@es
Martin Pule
@nl
Martin Pule
@sl
prefLabel
Martin Pule
@ast
Martin Pule
@en
Martin Pule
@es
Martin Pule
@nl
Martin Pule
@sl
P106
P21
P31
P496
0000-0002-8347-9867